ACURA PHARMACEUTICALS, INC: debt financing — Acura gets $200k more loans from AD Pharma; warns cash may run out by mid-July 2025

ACURA PHARMACEUTICALS, INC

Principal balance on AD Pharma secured note now $8,194,279; accrued interest ~$721k.
Two new $100k loans received June 3 and June 20, 2025; interest at 5.25% (7.5% default).
AD Pharma, which owns 65% of Acura's common stock, is the lender; controlled by Mr. Schutte.
Without additional financing by mid-July 2025, Acura may furlough/lay off employees or seek bankruptcy protection.
Company states no assurance additional financing will be obtained; proceeds used for day-to-day operations.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of loans of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: loans of $100,000
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On each of June 3, 2025 and June 20, 2025, we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma"). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $8,194,279 with accrued interest of approximately $721,000 as of June 20 2025, and bears interest at 5.25% ("Note").

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-061980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.